266 related articles for article (PubMed ID: 38236310)
21. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade.
Lin CC; Wu YT; Yang WC; Tsai MJ; Liu JS; Yang CY; Li SY; Ou SM; Tarng DC; Hsu CC
PLoS One; 2017; 12(12):e0189126. PubMed ID: 29216260
[TBL] [Abstract][Full Text] [Related]
22. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis.
Nakamura T; Obata J; Kimura H; Ohno S; Yoshida Y; Kawachi H; Shimizu F
Kidney Int; 1999 Mar; 55(3):877-89. PubMed ID: 10027924
[TBL] [Abstract][Full Text] [Related]
23. Diverse roles of TGF-β/Smads in renal fibrosis and inflammation.
Lan HY
Int J Biol Sci; 2011; 7(7):1056-67. PubMed ID: 21927575
[TBL] [Abstract][Full Text] [Related]
24. Loss of angiotensin-converting enzyme 2 enhances TGF-β/Smad-mediated renal fibrosis and NF-κB-driven renal inflammation in a mouse model of obstructive nephropathy.
Liu Z; Huang XR; Chen HY; Penninger JM; Lan HY
Lab Invest; 2012 May; 92(5):650-61. PubMed ID: 22330342
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA mimics that target the placental renin-angiotensin system inhibit trophoblast proliferation.
Arthurs AL; Lumbers ER; Pringle KG
Mol Hum Reprod; 2019 Apr; 25(4):218-227. PubMed ID: 30869150
[TBL] [Abstract][Full Text] [Related]
26. [Angiotensin II receptor blockers: current status and future prospects].
Corvol P; Plouin PF
Drugs; 2002; 62 Spec No 1():53-64. PubMed ID: 12036389
[TBL] [Abstract][Full Text] [Related]
27. Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation.
Carvajal G; Rodríguez-Vita J; Rodrigues-Díez R; Sánchez-López E; Rupérez M; Cartier C; Esteban V; Ortiz A; Egido J; Mezzano SA; Ruiz-Ortega M
Kidney Int; 2008 Sep; 74(5):585-95. PubMed ID: 18509316
[TBL] [Abstract][Full Text] [Related]
28. Patchouli alcohol against renal fibrosis of spontaneously hypertensive rats via Ras/Raf-1/ERK1/2 signalling pathway.
Li J; Hu G; Liu W; Cao X; Chen G; Peng F; Xiaofang X; Peng C
J Pharm Pharmacol; 2023 Jul; 75(7):995-1010. PubMed ID: 37177974
[TBL] [Abstract][Full Text] [Related]
29. The Therapeutic Potential of Targeting the Angiotensin Pathway as a Novel Therapeutic Approach to Ameliorating Post-surgical Adhesions.
Khalili-Tanha G; Khalili-Tanha N; Nazari SE; Chaeichi-Tehrani N; Khazaei M; Aliakbarian M; Hassanian SM; Ghayour-Mobarhan M; Ferns GA; Avan A
Curr Pharm Des; 2022; 28(3):180-186. PubMed ID: 34176457
[TBL] [Abstract][Full Text] [Related]
30. TGF-β/BMP proteins as therapeutic targets in renal fibrosis. Where have we arrived after 25 years of trials and tribulations?
Muñoz-Félix JM; González-Núñez M; Martínez-Salgado C; López-Novoa JM
Pharmacol Ther; 2015 Dec; 156():44-58. PubMed ID: 26493350
[TBL] [Abstract][Full Text] [Related]
31. Intrarenal renin-angiotensin system activity is augmented after initiation of dialysis.
Ohashi N; Isobe S; Ishigaki S; Suzuki T; Ono M; Fujikura T; Tsuji T; Kato A; Ozono S; Yasuda H
Hypertens Res; 2017 Apr; 40(4):364-370. PubMed ID: 27761002
[TBL] [Abstract][Full Text] [Related]
32. Angiotensin-(1-7): A Novel Peptide to Treat Hypertension and Nephropathy in Diabetes?
Padda RS; Shi Y; Lo CS; Zhang SL; Chan JS
J Diabetes Metab; 2015 Oct; 6(10):. PubMed ID: 26793405
[TBL] [Abstract][Full Text] [Related]
33. ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension.
Mendoza-Torres E; Oyarzún A; Mondaca-Ruff D; Azocar A; Castro PF; Jalil JE; Chiong M; Lavandero S; Ocaranza MP
Ther Adv Cardiovasc Dis; 2015 Aug; 9(4):217-37. PubMed ID: 26275770
[TBL] [Abstract][Full Text] [Related]
34. Molecular Mechanisms Involved in Intrarenal Renin-Angiotensin and Alternative Pathways in Diabetic Nephropathy - A Review.
Bahreini E; Rezaei-Chianeh Y; Nabi-Afjadi M
Rev Diabet Stud; 2021; 17(1):1-10. PubMed ID: 34289001
[TBL] [Abstract][Full Text] [Related]
35. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway.
Wolf G
Kidney Int; 2006 Dec; 70(11):1914-9. PubMed ID: 16985515
[TBL] [Abstract][Full Text] [Related]
36. Impact of angiotensin II on the kidney: does an angiotensin II receptor blocker make sense?
Hollenberg NK
Am J Kidney Dis; 2000 Sep; 36(3 Suppl 1):S18-23. PubMed ID: 10986155
[TBL] [Abstract][Full Text] [Related]
37. Renin-angiotensin system blockade in patients with chronic kidney disease: benefits, problems in everyday clinical use, and open questions for advanced renal dysfunction.
Loutradis C; Price A; Ferro CJ; Sarafidis P
J Hum Hypertens; 2021 Jun; 35(6):499-509. PubMed ID: 33654237
[TBL] [Abstract][Full Text] [Related]
38. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
[TBL] [Abstract][Full Text] [Related]
39. Regulation of epithelial mesenchymal transition by the renin-angiotensin system: a role for klotho in renal tubular epithelial cells.
Yang Z; Zhan YW; Huang YY; Huang W; Zhan F; Lin SD
J Biol Regul Homeost Agents; 2020; 34(1):57-67. PubMed ID: 32466632
[TBL] [Abstract][Full Text] [Related]
40. Adjunctive therapy with statins reduces residual albuminuria/proteinuria and provides further renoprotection by downregulating the angiotensin II-AT1 pathway in hypertensive nephropathy.
Zhang Z; Li Z; Cao K; Fang D; Wang F; Bi G; Yang J; He Y; Wu J; Wei Y; Song X
J Hypertens; 2017 Jul; 35(7):1442-1456. PubMed ID: 28244896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
